Torrent Pharmaceuticals Limited, a leading Indian pharmaceutical company, held its 52nd Annual General Meeting (AGM) on July 28, 2025, via video conferencing. The shareholders approved all 12 proposed resolutions, marking significant decisions for the company's future.

Key Approvals

Shareholders gave their nod to several important matters:

• Adoption of standalone and consolidated financial statements for the year ended March 31, 2025
• Confirmation of an interim dividend of ₹26.00 per share and declaration of a final dividend of ₹6.00 per share
• Appointment of Aman Mehta as Managing Director and approval of his remuneration
• Enhancement of borrowing limits from ₹15,000.00 crore to ₹26,000.00 crore
• Authorization for loan, guarantee, and investment enhancements under Section 186 of the Companies Act

Appointment of Aman Mehta

One of the most significant outcomes of the AGM was the appointment of Aman Mehta as the new Managing Director. Shareholders showed strong support for this decision, with 99.80% voting in favor of his appointment and 97.41% approving his compensation package.

Aman Mehta, who holds a bachelor's degree in economics from Boston University and an MBA from Columbia University, brings over a decade of experience within the Torrent Group. He has been instrumental in driving growth initiatives, strategic evaluations, and fostering a high-performance culture in the company.

Financial Decisions

The company's shareholders approved the enhancement of borrowing limits to ₹26,000.00 crore, indicating potential plans for expansion or significant investments. They also authorized the issuance of equity shares, including convertible bonds/debentures, which could provide additional capital for the company's growth strategies.

Other Approvals

Other key resolutions passed at the AGM included:

• Ratification of cost auditors' remuneration for 2025-26
• Appointment of M/s. M. C. Gupta & Co. as Secretarial Auditors for a five-year term
• Approval for enhancement of limits for loans, guarantees, and investments under Section 186 of the Companies Act

Voting Process

The voting process included both remote e-voting from July 24-27, 2025, and e-voting during the AGM. Rajesh Parekh, a practicing company secretary, oversaw the process as the scrutinizer, ensuring transparency and compliance with regulatory requirements.

The strong shareholder support across all resolutions reflects confidence in Torrent Pharmaceuticals' management and strategic direction. With these approvals, the company is well-positioned to pursue its growth plans and navigate the evolving pharmaceutical landscape.

Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key markets and improved profitability.

Financial Highlights

• Revenue increased by 11% year-over-year to Rs 3,178.00 crore
• Net profit surged by 20% to Rs 548.00 crore
• Operating EBITDA grew by 14% to Rs 1,032.00 crore
• EBITDA margin improved to 32.50%
• Gross margin remained steady at 76.00%

Market Performance

India

The company's performance in its home market remained strong:

• India revenues rose by 11% to Rs 1,811.00 crore
• Chronic business grew by 13%, outpacing the Indian Pharmaceutical Market (IPM) growth of 9%
• 21 brands featured in the Top 500 IPM brands, with 14 brands generating over Rs 100.00 crore in sales

Brazil

Torrent Pharma continued to make strides in the Brazilian market:

• Brazil revenues increased by 11% to Rs 218.00 crore
• Constant currency revenues grew by 16% to R$ 143.00 million
• The company outperformed the market, growing at 14% compared to the overall market growth of 5%
• 62 products are currently under review by ANVISA, the Brazilian health regulatory agency

Germany

Despite challenges, the German business showed resilience:

• Germany revenues grew by 9% to Rs 308.00 crore
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

The US market demonstrated strong growth:

• US revenues surged by 19% to Rs 308.00 crore
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches have achieved targeted market shares

R&D Investment

Torrent Pharma continued to invest in research and development:

• R&D spend increased by 16% to Rs 157.00 crore, representing 5% of total revenues

Future Outlook

Torrent Pharmaceuticals is poised for further growth with its strong presence in both domestic and international markets. The company's robust pipeline of products under review in Brazil and its recent successful launches in the US market indicate potential for continued expansion.

As Torrent Pharma maintains its position as the 7th ranked company in the Indian Pharmaceutical Market and continues to be among the top 5 in key therapeutic segments, it is well-positioned to capitalize on growth opportunities in the pharmaceutical sector.

With its strong financial performance, continued focus on key therapeutic areas, and expansion in international markets, Torrent Pharmaceuticals Limited demonstrates resilience and growth potential in the competitive pharmaceutical industry.